• Introduction
• 16 min
  1. Psychopharmacology: structural aspects of the brain

  • Prof. Brian Leonard
• 66 min
  2. The nature of chemical neurotransmission

  • Prof. Brian Leonard
• 28 min
  3. Psychotropic drugs

  • Prof. Brian Leonard
• 26 min
  4. Psychopharmacology of anxiety disorders

  • Prof. Brian Leonard
• 35 min
  5. Psychopharmacology of depression

  • Prof. Brian Leonard
• 48 min
  6. Psychopharmacology of mania and schizophrenia

  • Prof. Brian Leonard
• 45 min
  7. The role of stress and immune system in psychiatric disorders

  • Prof. Brian Leonard
• Introduction to Genetic Investigations of Complex Traits
• 39 min
  8. Genetic association studies, TDT and the candidate gene approach

  • Dr. Jo Knight
• Genetics and Pharmacokinetics of Psychotropic Drugs
• 34 min
  9. Genetics of phase I enzymes

  • Prof. Aiming Yu
• 36 min
  10. Phase II metabolism

  • Prof. Ann Daly
• Genetics and Pharmacodynamics of Psychotropic Drugs
• 25 min
  11. Genetics and psychotropic drugs: present and future clinical applications

  • Dr. Chiara Fabbri
• 25 min
  12. Influence of neurotransmitter receptor variants on interactions with psychotropic drugs

  • Dr. Maria Arranz
• 51 min
  13. Pharmacogenetics of antidepressants

  • Prof. Alessandro Serretti
• Clinical Applications of Psychopharmacogenetics
• 41 min
  14. Of genes and drugs: genetic determinants of adverse drug reactions

  • Dr. Mario Masellis
• 35 min
  15. Cocaine and amphetamine addiction genetics

  • Dr. Gerome Breen
• 29 min
  16. Tailoring psychiatric treatment using genetic information: pharmacogenetic prediction of treatment response

  • Dr. Maria Arranz
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  17. Genetic, environmental and other design issues relevant for pharmacogenetics studies

  • Dr. Ridha Joober
• 37 min
  18. Genetic determinants of metabolism: clinical applications in psychiatry

  • Prof. Julia Stingl (formerly Kirchheiner)
• 36 min
  19. Rapid methods for the genetic determination of pharmacokinetic status

  • Dr. Paul Debenham
• 47 min
  20. Genetic polymorphisms influencing response to lithium

  • Prof. Alessandro Serretti
• 28 min
  21. Genetic determinants of antipsychotic-induced weight gain

  • Prof. Gavin Reynolds
• 59 min
  22. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 1

  • Dr. Vincenzo Basile
• 50 min
  23. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 2

  • Dr. Vincenzo Basile
• 37 min
  24. Genetic determinants of agranulocytosis

  • Dr. Michael Dettling
• 52 min
  25. Genetic polymorphisms influencing the response of antidepressants

  • Prof. Alessandro Serretti

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Schizophrenia: symptoms
3. Schizophrenia: the therapeutic challenge
4. Hypothesized DA/5-HT pathways in schizophrenia
5. DA and 5-HT: hypothesis of schizophrenia
6. DA pathways for movement in basal ganglia
7. Other ADRs to antipsychotics: elevated prolactin
8. Variation in response and ADRs
9. Psychiatric pharmacogenetics: definition
10. Biological-environmental-demographic interactions
11. Complex trait genetics
12. Our clinical sample
13. Genetic association strategy
14. Tardive dyskinesia (TD): pharmacogenetic studies
15. TD: symptoms
16. TD: oro-facial symptoms
17. TD and tardive dystonia: truncal symptoms
18. TD: postulated pathophysiology
19. TD: genetic rationale
20. Hypothesis: variation and susceptibility to TD
21. Pharmacodynamic candidates: DRD3 gene
22. Neuroanatomical distributions of DA receptors
23. Why DRD3?
24. DRD3 variation
25. DRD3 Msc I polymorphism: mean AIMS scores
26. Stratified analysis
27. Brain metabolism and DRD3 genotype: FDG-PET
28. TD and DRD3 gene: references (1)
29. TD and DRD3 gene: references (2)
30. TD and DRD3 gene: meta-analysis
31. Pharmacodynamic candidates: 5-HTR2A gene
32. DRD and 5-HTR genes: hypotheses of TD
33. Dopaminergic and serotonergic interactions
34. Antipsychotics and receptor binding profile
35. Atypical antipsychotics: fast-on fast-off theory (1)
36. Atypical antipsychotics: fast-on fast-off theory (2)
37. Theories of "atypical" antipsychotic action
38. HTR2A polymorphisms
39. HTR2A polymorphism: mean AIMS scores
40. TD and HTR2A gene: references
41. TD and other HTR genes: references
42. TD and HTR2A gene: meta-analysis

Topics Covered

• Postulated mechanisms of schizophrenia
• Dopaminergic pathways in schizophrenia
• The Pharmacogenetic paradigm
• Pharmacokinetic-pharmacodynamic-environmental interactions
• Complex trait genetics
• Antipsychotic adverse reactions
• Tardive dyskinesia
• Postulated mechanisms
• Genetic association studies of TD
• Candidate genes in TD
• Pharmacodynamics and TD: a look at dopaminergic and serotonergic candidates

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Vincenzo Basile has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.